The use of supplemental hydrocortisone in the management of persistent pulmonary hypertension of the newborn.

Journal Article (Journal Article)

OBJECTIVE: Characterize association between hydrocortisone receipt and hospital outcomes of infants with persistent pulmonary hypertension of the newborn (PPHN). STUDY DESIGN: Cohort study of infants ≥34 weeks with PPHN who received inhaled nitric oxide at <7 days of age (2010-2016). We generated propensity scores, and performed inverse probability-weighted regression to estimate hydrocortisone effect on outcomes: death, chronic lung disease (CLD), oxygen at discharge. RESULTS: Of 2743 infants, 30% received hydrocortisone, which was associated with exposure to mechanical ventilation, sedatives, paralytics, or vasopressors (p < 0.001). There was no difference in death, CLD, or oxygen at discharge. In infants with meconium aspiration syndrome, hydrocortisone was associated with decreased oxygen at discharge (odds ratio 0.56; 95% confidence interval 0.21, 0.91). CONCLUSIONS: There was no association between hydrocortisone receipt and death, CLD, or oxygen at discharge in our cohort. Prospective studies are needed to evaluate the effectiveness of hydrocortisone in infants with PPHN.

Full Text

Duke Authors

Cited Authors

  • Aleem, S; Robbins, C; Murphy, B; Elliott, S; Akinyemi, C; Paredes, N; Tolia, VN; Zimmerman, KO; Goldberg, RN; Benjamin, DK; Greenberg, RG

Published Date

  • April 2021

Published In

Volume / Issue

  • 41 / 4

Start / End Page

  • 794 - 800

PubMed ID

  • 33589734

Pubmed Central ID

  • PMC8052278

Electronic International Standard Serial Number (EISSN)

  • 1476-5543

Digital Object Identifier (DOI)

  • 10.1038/s41372-021-00943-9


  • eng

Conference Location

  • United States